In July, FDA announced generic drug product-specific guidances that included 48 finalized, 13 revisions, and 21 new product documents. The guidances describe the agency’s current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific reference-listed drugs. For product-specific guidances published in June, click here.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
